Affiliation:
1. Federal State Unitary Enterprise Research & Production Center “Pharmaceutical Protection” of the Federal Medical Biological Agency
2. RMC “Home of pharmacy” JSC
3. Pavlov First Saint Petersburg State Medical University; Saint Petersburg State Chemical Pharmaceutical University
Abstract
The aim of the study was to clarify the toxicity of mefloquine and to evaluate the effectiveness of its use for Syrian hamsters infected with sARS-Cov-2.Material and methods. The experiments were performed on 96 Syrian hamsters. The toxicity of mefloquine was determined with a single administration, as well as with a course of administration at doses comparable to therapeutic for humans. To study the effectiveness of the drug against SARS-CoV-2 infection, a comprehensive indicator of the state of lung tissue and a comparison of the dynamics of viral load in the lungs were used.Results. The LD50 of mefloquine with a single oral administration is 817 mg/kg, the maximum tolerated dose is 600 mg/kg. When administered for 7 days at a cumulative dose of 900 mg/kg, no death was observed. Administration of mefloquine to animals infected with SARS-CoV-2 was accompanied by a decrease in the severity of lung damage and a faster decrease of viral load in the lung tissue.
Publisher
Russian Register of Potentially Hazardous Chemical and Biological Substances
Reference20 articles.
1. Temporary guidelines. Prevention, diagnosis and treatment of the new coronavirus infection «COVID-19». Version 4. 27.03.2020. Moscow: Ministry of Health of the Russian Federation [ Vremenny'e metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoy infekcii «COVID-19». Versiya 4. 27.03.2020. Moscow: Ministerstvo zdravooxraneniya Rossijskoj Federacii, 2020. 2020. (in Russian)
2. Sarma P., Kaur H., Kumar H., Mahendru D., Avti P., Bhattacharyya A., et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020; 92(7): 776-85.
3. Tang W., Cao Z., Han M., Wang Z., Chen J., Sun W. [et al.]. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369: m1849.
4. WHO Solidarity Trial Consortium, Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V., Abdool Karim Q., et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021; 384(6): 497-511.
5. Biot C., Daher W., Chavain N., Fandeur T., Khalife J., Dive D., De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006; 49(9): 2845-9.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献